v3.26.1
Information Concerning the Group's Consolidated Operations - Additional Information (Detail)
€ in Millions
 12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2025
EUR (€)
Consolidated operations [line items]        
Revenues $ 72,949,000 $ 41,505,000 $ 755,000  
Decrease in other income 1,100,000 1,100,000    
Increase in research and development expense 3,000,000 2,900,000    
Increase in selling, general and administrative expenses 700,000 2,300,000    
Decrease in other operating income (expenses) 200,000 2,000,000    
Research tax credit litigation settled     700,000  
Research tax credit litigations accrual     500,000  
Commercial litigation     500,000  
Decrease /increase in financial income 28,300,000 (22,900,000)    
Increase (decrease) in Income from cash, cash equivalents and financial assets (1,800,000) 7,700,000    
Decrease in foreign exchange gains (losses)   4,500,000    
Foreign exchange gain 5,862,000 13,079,000 17,618,000  
Decrease /increase in financial Expenses 29,500,000 19,000,000    
Increase / (Decrease) in interest expense on lease liabilities $ 700,000 400,000    
Percentage of taxable income subject to annual limitation 80.00%      
Annual Limit to carryforwards use against future taxable profit 50.00%     50.00%
Increase (decrease) in foreign exchange gains $ 7,200,000      
Increase in foreign exchange gains 22,200,000      
Gain in fair value of SIA derivative instrument 14,300,000   14,300,000  
Gain on change in fair value 765,000 20,009,000 245,000  
Loss on fair value measurement (15,039,000) (8,366,000) (20,813,000)  
Loss on fair value measurement (6,700,000)      
Gain in fair value of foreign exchange derivatives 800,000      
Increase/ Decrease in foreign exchange losses   7,600,000    
Foreign exchange loss $ 27,919,000 $ 5,754,000 $ 13,402,000  
Effective income tax rate (0.62%) 0.00% 0.32%  
Deferred tax assets related to accumulated tax loss carryforwards and federal R&D tax credits $ 0 $ 0 $ 0  
Top of Range [member]        
Consolidated operations [line items]        
Annual limit to carryforwards use against future taxable profit amount | €       € 1.0
France [Member]        
Consolidated operations [line items]        
Revenues 72,949,000 41,505,000 755,000  
Accumulated tax losses 775,900,000 612,900,000 590,000,000  
United States [member]        
Consolidated operations [line items]        
Accumulated tax losses 36,200,000 29,200,000 29,800,000  
European Investment Bank Warrants [Member]        
Consolidated operations [line items]        
Loss in fair value recognized in profit and loss   5,700,000    
Loss on fair value measurement (14,700,000)      
European Investment Bank Loan [Member]        
Consolidated operations [line items]        
Interest expense on EIB loan   2,000,000    
Tranche A And Tranche B Warrants [Member]        
Consolidated operations [line items]        
Change in Fair Value of Europen Investment Bank     2,400,000  
Cytovia [Member]        
Consolidated operations [line items]        
Non-recurring gain (loss) in fair value measurement before derecognition     7,800,000  
Cibus Inc [Member]        
Consolidated operations [line items]        
Gain (loss) on change in fair value of our investment   2,300,000    
Cellectis, Inc. and Cellectis Biologics, Inc. [Member] | United States [member] | Federal Tax Authority [Member]        
Consolidated operations [line items]        
Accumulated tax losses 7,100,000      
Federal R&D tax credits, tax loss carryforwards 8,400,000      
Cellectis, Inc. and Cellectis Biologics, Inc. [Member] | United States [member] | State And Local Tax Authority [Member]        
Consolidated operations [line items]        
Accumulated tax losses $ 29,100,000      
State operating loss carryforwards expiration year 2035      
Cellectis, Inc. and Cellectis Biologics, Inc. [Member] | United States [member] | Top of Range [member] | Federal Tax Authority [Member]        
Consolidated operations [line items]        
Federal R&D tax credits, expiration period 2044      
Cellectis, Inc. and Cellectis Biologics, Inc. [Member] | United States [member] | Bottom of Range [member] | Federal Tax Authority [Member]        
Consolidated operations [line items]        
Federal R&D tax credits, expiration period 2035      
Licence Of Patents [Member]        
Consolidated operations [line items]        
Increase in depreciation and amortization expenses   1,200,000    
Research and development expenses [member]        
Consolidated operations [line items]        
Increase in personnel expenses $ 4,200,000      
Decrease in personnel expenses   2,900,000    
Decrease in stock-based compensation expense   1,900,000    
Increase in depreciation and amortization expenses 300,000 1,900,000    
Decrease in purchases and external expenses 1,500,000      
Purchases and external expenses 35,083,000 36,611,000 32,996,000  
Increase in purchases and external expenses   3,600,000    
Personnel expenses 38,466,000 34,253,000 37,158,000  
Selling General and Administrative Expense [Member]        
Consolidated operations [line items]        
Purchases and external expenses 9,800,000 9,200,000 6,700,000  
Increase in purchases and external expenses $ 600,000 $ 2,500,000    
AstraZeneca [member]        
Consolidated operations [line items]        
Percentage of Revenue 99.00% 86.00%    
Joint Collaboration and Research Agreement [Member] | AstraZeneca [member]        
Consolidated operations [line items]        
Revenues $ 18,800,000      
Revenue from performance obligations satisfied or partially satisfied in previous periods 5,000,000      
Subsequent Investment Agreement [Member]        
Consolidated operations [line items]        
Loss in fair value recognized in profit and loss     $ 5,700,000  
Astra Zeneca Ireland [Member] | Joint Collaboration and Research Agreement [Member]        
Consolidated operations [line items]        
Revenues 71,900,000 $ 35,500,000    
License Agreement with Servier [Member]        
Consolidated operations [line items]        
Revenue from performance obligations satisfied or partially satisfied in previous periods   $ 5,400,000    
Percentage of Revenue   12.00%    
Cibus Shares [Member]        
Consolidated operations [line items]        
Loss on fair value measurement $ (7,800,000)